ArticleBMC urology2026
Urinary exosomal miRNA profiling reveals sensitive non-invasive detection of bladder cancer.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary microRNAs (miRNAs) hold substantial promise as non-invasive biomarker candidates due to their molecular stability and tumor-selective expression signatures. This study integrates the high-throughput urinary miRNA landscape with clinical data to systematically identify robust, non-invasive biomarkers that facilitate the early diagnosis and better clinical management of urinary bladder cancer (UBC).
methodsUrine-derived miRNA sequencing was performed on UBC patients and healthy controls to delineate the miRNA expression profile. Computational filtering further excluded precursor form of miRNA, prioritizing the mature miRNA. Quantitative RT-PCR targeting an independent, age-matched cohort (n = 48) corroborated with the diagnostic potential of candidate miRNAs, evaluated through receiver operating characteristic (ROC) curves and area under the curve (AUC) analyses. RESULTS AND LIMITATIONS: Next-generation sequencing unveiled 865 annotated and 11 novel miRNAs, with UBC samples displaying greater miRNA diversity (708 known miRNAs) compared to relative controls (540). Among them, seven mature miRNAs were significantly dysregulated in UBC (p < 0.05), of which quantitative RT-PCR corroborated significant upregulation of miR-6724-5p, miR-1273 h-5p, miR-7704, miR-200-5p, and miR-10400-5p, with fold elevations of 1542.3, 1085.8, 1160.6, 2776.5, and 45.8, respectively (p < 0.01). Stage-stratified profiling underscored dynamic shifts in miRNA expression that correlated with tumor advancement. A three-miRNA panel (miR-6724-5p, miR-10400-5p, and miR-7704) exhibited superior diagnostic performance (AUC > 70%, sensitivity > 90%). However, this study was constrained to a single institute with a small sample size and a short follow-up period, which precluded the correlation between the identified biomarker miRNAs with cancer recurrence and patient survival.
conclusionIn this preliminary, single-centre study, mature urinary miRNAs demonstrated reproducible, stage-specific dysregulation in UBC. A combinatorial panel offered potential for a highly sensitive, specific, and non-invasive detection method. These findings propel further multicentre studies to validate the observed signatures, supporting their potential towards future clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.